References
1. Scarpignato C, Pelosini I, Di Mario F. Acid suppression therapy:
where do we go from here? Dig Dis. 2006;24(1-2):11-46.
doi:10.1159/000091298
2. Tennant SM, Hartland EL, Phumoonna T, et al. Influence of gastric
acid on susceptibility to infection with ingested bacterial pathogens.
Infect Immun. 2008;76(2):639-645. doi:10.1128/IAI.01138-07
3. Yang ZY, Huang Y, Ganesh L, et al. pH-dependent entry of severe acute
respiratory syndrome coronavirus is mediated by the spike glycoprotein
and enhanced by dendritic cell transfer through DC-SIGN. J Virol.
2004;78(11):5642-5650. doi:10.1128/JVI.78.11.5642-5650.2004
4. Bavishi C, Dupont HL. Systematic review: the use of proton pump
inhibitors and increased susceptibility to enteric infection. Aliment
Pharmacol Ther. 2011;34(11-12):1269-1281.
doi:10.1111/j.1365-2036.2011.04874.x
5. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of
enteric infection in patients taking acid suppression. Am J
Gastroenterol. 2007;102(9):2047-2057.
doi:10.1111/j.1572-0241.2007.01275.x
6. Zhu, N., et al. A Novel Coronavirus from Patients with Pneumonia in
China, 2019. N Engl J Med 382, 727-733 (2020).
7. Wu, Z. & McGoogan, J.M. Characteristics of and Important Lessons
From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary
of a Report of 72314 Cases From the Chinese Center for Disease Control
and Prevention. JAMA (2020).
8. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for
Gastrointestinal Infection of SARS-CoV-2. Gastroenterology.
2020;158(6):1831-1833.e3. doi:10.1053/j.gastro.2020.02.055
9. Lin L, Jiang X, Zhang Z, et al. Gastrointestinal symptoms of 95 cases
with SARS-CoV-
2 infection. Gut 2020;69:997–1001.
10. Zhang H, Kang Z, Gong H, et al. Digestive system is a potential
route of COVID-19: an analysis of single-cell coexpression pattern of
key proteins in viral entry process. Gut
2020;69:1010–8.
11. American Journal of Gastroenterology. Increase Risk of COVID-19
Among Users of Proton Pump Inhibitors.
https://journals.lww.com/ajg/Documents/AJG-20-1811_R1(PUBLISH%20AS%20WEBPART).pdf.
Accessed August 01, 2020.
12. Lee SW, Ha EK, Yeniova AÖ, et al. Severe clinical outcomes of
COVID-19 associated with proton pump inhibitors: a nationwide cohort
study with propensity score matching. Gut Published Online First: 30
July 2020. doi: 10.1136/gutjnl-2020-322248
13. Freedberg DE, Conigliaro J, Wang TC, Tracey KJ, Callahan MV, Abrams
JA, on behalf of the Famotidine Research Group Famotidine Research
Group, Sobieszczyk ME,
Markowitz DD, Gupta A, O’Donnell MR, Li J, Tuveson DA, Jin Z, Turner WC,
Landry DW, Famotidine Use is Associated with Improved Clinical Outcomes
in Hospitalized COVID-19 Patients: A Propensity Score Matched
Retrospective Cohort Study, Gastroenterology (2020), doi:
https://doi.org/10.1053/j.gastro.2020.05.053.
14. Janowitz T, Gablenz E, Pattinson D, et al. Gut Epub ahead of print:
[01 August 2020]. doi:10.1136/gutjnl-2020-321852
15. Vilcu A, Sabatte L, Blanchon T, et al. Association Between Acute
Gastroenteritis and Continuous Use of Proton Pump Inhibitors During
Winter Periods of Highest Circulation of Enteric Viruses. JAMA Netw
Open. 2019;2(11):e1916205. doi:10.1001/jamanetworkopen.2019.16205
16. Sarkar M, Hennessy S, Yang Y-X. Proton-Pump inhibitor use and the
risk for community-acquired pneumonia. Ann Intern Med 2008;149:391–8.
17. Laheij RJF, Sturkenboom MCJM, Hassing R-J, et al. risk of
community-acquired
pneumonia and use of gastric acid-suppressive drugs. JAMA
2004;292:1955–60.
18. Wang C-H, Li C-H, Hsieh R, et al. Proton pump inhibitors therapy and
the risk of pneumonia: a systematic review and meta-analysis of
randomised controlled trials and observational studies. Expert Opin Drug
Saf 2019;18:163–72.
19. Darnell ME, Subbarao K, Feinstone SM, et al. Inactivation of the
coronavirus that induces severe acute respiratory syndrome, SARS-CoV. J
Virol Methods 2004;121:85-91.
20. Lamers MM, Beumer J, van der Vaart J, et al. SARS-CoV-2 productively
infects human gut enterocytes. Science 2020.
21. Bourinbaiar AS, Fruhstorfer EC. The effect of histamine type 2
receptor antagonists on human immunodeficiency virus (HIV) replication:
Identification of a new class of antiviral agents. Life Sci.
1996;59(23):365–370
22. Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for
SARS-CoV-2 and discovery of potential drugs by computational methods.
Acta Pharm Sin B. 2020;. https://doi.org/10.1016/j.
apsb.2020.02.008.
23. Clinical Trials. Multi-site Adaptive Trials for COVID-19.
https://clinicaltrials.gov/ct2/show/NCT04370262. Accessed August 01,
2020.
24. Miehlke S, Madisch A, Kirsch C, et al. Intragastric acidity during
treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg
twice daily–a randomised, two-way crossover study. Aliment Pharmacol
Ther 2005;21:963-7.
25. Johnson DA, Stacy T, Ryan M, et al. A comparison of esomeprazole and
lansoprazole for control of intragastric pH in patients with symptoms of
gastro-oesophageal reflux disease. Aliment Pharmacol Ther
2005;22:129-34.
26. Katz PO, Castell DO, Chen Y, et al. Intragastric acid suppression
and pharmacokinetics of twice-daily esomeprazole: a randomised,
three-way crossover study. Aliment Pharmacol Ther 2004;20:399-406.